Glycoprotein la gene C807T polymorphism and risk for major adverse cardiacevents within the first 30 days after coronary artery stenting

Citation
N. Von Beckerath et al., Glycoprotein la gene C807T polymorphism and risk for major adverse cardiacevents within the first 30 days after coronary artery stenting, BLOOD, 95(11), 2000, pp. 3297-3301
Citations number
46
Categorie Soggetti
Hematology,"Cardiovascular & Hematology Research
Journal title
BLOOD
ISSN journal
00064971 → ACNP
Volume
95
Issue
11
Year of publication
2000
Pages
3297 - 3301
Database
ISI
SICI code
0006-4971(20000601)95:11<3297:GLGCPA>2.0.ZU;2-8
Abstract
The glycoprotein complex Ia/IIa (GP Ia/IIa) is a major collagen receptor on platelets and other cell types, Recently, linked polymorphisms within the coding region of the GP la gene (C807T and G873A) were identified that are related to GP Ia/IIa surface expression. The T807/A873 allele is associated with high expression, whereas the C807/G873 allele is associated with low surface expression of GP Ia/IIa, Subsequently, the T807 allele was found to be associated with coronary and cerebral infarction in younger patients. P latelet adhesion to the vessel wall plays a pivotal role in thrombosis afte r coronary artery stent placement, The goal of this study was to test wheth er C807T polymorphism is associated with a higher incidence of thrombotic e vents following coronary stenting, Consecutive patients treated with corona ry stent placement (n = 1797) were genotyped for C807T polymorphism with po lymerase chain reaction and allele-specific fluorogenic probes, The composi te end point was defined as death, myocardial infarction, or urgent target vessel revascularization within 30 days of stent implantation. The genotype distribution of the study population was CC in 36.5%, CT in 46.7%, and TT in 16.8% of the patients. The incidence of the composite end point was 6.5% in T allele carriers and 5.3% in noncarriers (odds ratio for T allele carr iage 1.23 [95% confidence interval, 0.81-1.86], P=.33), After adjusting for other baseline characteristics, the odds ratio for the composite end point was 1.15 (0.76-1.75). Therefore, C807T genotype has no significant influen ce on the major adverse events occurring after coronary artery stenting. (B lood, 2000;95:3297-3301) (C) 2000 by The American Society of Hematology.